Back to announcement
KLBF - Penjelasan Perubahan Liabilitas_final.pdf
Financial statement Text extracted KLBFSource file signed link, expires in 15 minutes
Extracted text 2
Page 1
No. : 059/CSEC-KF/VII-2026 Jakarta, 30 Juli 2026 Lampiran : - Kepada Yth./To Otoritas Jasa Keuangan Gedung Sumitro Djojohadikusumo Jl. Lapangan Banteng Timur 2-4 Jakarta 10710 Indonesia U.p.: Kepala Eksekutif Pengawas Pasar Modal Direksi PT Bursa Efek Indonesia Indonesia Stock Exchange Building, Tower I Jl. Jend. Sudirman Kav. 52-53 Jakarta 12190 Indonesia U.p.: Direktur Pencatatan Perihal : Penjelasan PT Kalbe Farma Tbk dan Subject: Explanation by PT Kalbe Farma Tbk Entitas Anak (“Perseroan) tentang and Its Subsidiaries (“the Company”) Perubahan Lebih dari 20% (Dua Puluh Regarding the Change of More Than 20% Persen) pada Total Liabilitas (Twenty Percent) in Total Liabilities Dengan hormat, With respect, Merujuk pada Peraturan Bursa Efek Indonesia Referring to Indonesia Stock Exchange Nomor I-E tentang Kewajiban Penyampaian Regulation Number I-E on the Obligation to Informasi, butir III.1.1.4. dimana apabila terdapat Submit Information, item III.1.1.4, whereby in the perubahan lebih dari 20% (dua puluh persen) event of a change exceeding 20% (twenty pada Jumlah Aset dan/atau Jumlah Liabilitas percent) in the Total Assets and/or Total pada Laporan Keuangan Interim atau Laporan Liabilities in the Interim Financial Statements or Keuangan Tahunan periode tahun buku the Annual Financial Statements for the current berjalan dibandingkan dengan Laporan financial year compared with the most recent Keuangan Tahunan Auditan terakhir maka Audited Annual Financial Statements, the Listed bersamaan dengan penyampaikan Laporan Company is required, concurrently with the Keuangan Perusahaan Tercatat wajib submission of its Financial Statements, to memberikan penjelasan tertulis kepada Bursa provide the Exchange with a written explanation tentang penyebab perubahan berikut regarding the causes of such change and pendapat manajemen tentang dampak management’s opinion on its impact on the perubahan tersebut terhadap kinerja Listed Company’s financial performance during keuangan Perusahaan Tercatat pada tahun the current year. berjalan. Berdasarkan Laporan Keuangan Belum Diaudit Based on the Consolidated Unaudited Financial Konsolidasian tanggal 30 Juni 2026, total Statements as of June 30, 2026, total liabilities liabilitas adalah sebesar Rp7.314.030 juta, amounted to Rp7,314,030 million, representing mengalami kenaikan sebesar Rp1.343.185 juta an increase of Rp1,343,185 million or 22.5% atau setara dengan 22,5% jika dibandingkan compared to the prior period. The increase in dengan periode sebelumnya. Kenaikan total total liabilities was primarily attributable to liabilitas terutama lebih disebabkan oleh higher short-term bank loans and trade PT. KALBE FARMA Tbk. Head Office : Gedung KALBE, Jl. Let. Jend. Suprapto Kav. 4, Jakarta 10510, P.O. Box 3105 JAK, Jakarta, Indonesia. Tel. (021) 42873888 - 89 Fax. (021) 42873680 Factory : Kawasan Industri Delta Silicon, Jl. M. H. Thamrin Blok A3 – 1, Lippo Cikarang, Bekasi 17550, P.O. Box 371 Bekasi 17037. Indonesia. Tel. (021) 89907333 Fax. (021) 8972874 Info@kalbe.co.id
Page 2
kenaikan utang bank jangka pendek serta payables. The increase in short-term bank loans utang usaha. Kenaikan utang bank jangka was mainly driven by working capital needs, pendek terutama didorong oleh penarikan while the increase in trade payables mainly arose pinjaman untuk kebutuhan modal kerja from the purchase of raw materials and finished sedangkan kenaikan utang usaha terutama goods which was consistent with the Company’s berasal dari pembelian bahan baku dan barang business development. jadi seiring dengan perkembangan bisnis Perseroan. Manajemen Perseroan berpendapat bahwa In Management’s view, the aforementioned perubahan tersebut sejalan dengan strategi changes are in line with the Company’s business bisnis Perseroan serta tidak berdampak pada strategy and do not adversely impact the penurunan kinerja Perseroan. Perseroan Company’s performance. The Company mampu menjaga rasio utang melalui continues to maintain debt ratios through pengelolaan likuiditas yang baik. prudent liquidity management. Demikian kami sampaikan dan atas We hereby submit this information and thank perhatiannya kami ucapkan terima kasih. you for your kind attention. Hormat kami/Yours sincerely PT Kalbe Farma Tbk Maria Teresa Fabiola Corporate Secretary PT. KALBE FARMA Tbk. Head Office : Gedung KALBE, Jl. Let. Jend. Suprapto Kav. 4, Jakarta 10510, P.O. Box 3105 JAK, Jakarta, Indonesia. Tel. (021) 42873888 - 89 Fax. (021) 42873680 Factory : Kawasan Industri Delta Silicon, Jl. M. H. Thamrin Blok A3 – 1, Lippo Cikarang, Bekasi 17550, P.O. Box 371 Bekasi 17037. Indonesia. Tel. (021) 89907333 Fax. (021) 8972874 Info@kalbe.co.id
Names mentioned 8 people and organisations named in the text · linked when the evidence is strong
unresolved
org
PT Bursa Efek Indonesia Indonesia Stock Exchange Building
p.1
unresolved
org
Indonesia Stock Exchange
p.1 ×2
unresolved
person
H. Thamrin
p.1 ×2
unresolved
person
Maria Teresa Fabiola
· Corporate Secretary
p.2
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.